You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SB 258719 hydrochloride
Selective 5-HT7 receptor antagonist that displays > 100-fold selectivity over a range of other receptors. Reverses the hypothermic effect of 5-CT in mice following i.p. administration.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 374.97. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.67 mL||13.33 mL||26.67 mL|
|5 mM||0.53 mL||2.67 mL||5.33 mL|
|10 mM||0.27 mL||1.33 mL||2.67 mL|
|50 mM||0.05 mL||0.27 mL||0.53 mL|
References are publications that support the biological activity of the product.
Forbes et al (1998) (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl)propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist. J.Med.Chem. 41 655 PMID: 9513592
Thomas et al (1998) Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br.J.Pharmacol. 124 1300 PMID: 9720804
Guscott et al (2003) The hypothermic effect of 5-CT in mice is mediated through the 5-HT7receptor. Neuropharmacology 44 1031 PMID: 12763096
If you know of a relevant reference for SB 258719 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: SB 258719 hydrochloride, SB 258719 hydrochloride supplier, Selective, 5-HT7, antagonists, Serotonin, Receptors, 5-Hydroxytryptamine, SB258719, hydrochloride, GlaxoSmithKline, GSK, 2726, Tocris Bioscience
3 Citations for SB 258719 hydrochloride
Citations are publications that use Tocris products. Selected citations for SB 258719 hydrochloride include:
Johnson et al (2011) Serotonin receptor activity is necessary for olfactory learning and memory in Drosophila melanogaster. Neuroscience 192 372 PMID: 21749913
Zhao et al (2015) Fisetin exerts antihyperalgesic effect in a mouse model of neuropathic pain: engagement of spinal serotonergic system. Front Synaptic Neurosci 5 9043 PMID: 25761874
Domínguez-Soto (2017) Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis. Sci Rep 7 14761 PMID: 29116249
Do you know of a great paper that uses SB 258719 hydrochloride from Tocris? Please let us know.
Reviews for SB 258719 hydrochloride
There are currently no reviews for this product. Be the first to review SB 258719 hydrochloride and earn rewards!
Have you used SB 258719 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.